Benmelstobart is under clinical development by Apollomics and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase I drugs for Small-Cell Lung Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Benmelstobart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Benmelstobart overview
Benmelstobart (Andervi) is a humanized PD-L1 monoclonal antibody. It is formulated as injectable solution for intravenous route of administration. Andervi is indicated for the treatment of patients with extensive-stage small cell lung cancer in combination with anlotinib hydrochloride capsules, carboplatin and etoposide.
Benmelstobart is under development for the treatment of cervical cancer, cervical cancer, advanced renal cell carcinoma, cholangiocarcinoma, esophageal squamous cell carcinoma, advanced hepatocellular carcinoma, non-small cell lung cancer, colon cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, melanoma, relapsed or refractory classical hodgkin's lymphoma soft tissue sarcoma including synovial sarcoma, leiomyosarcoma, alveolar soft part sarcoma, undifferentiated pluripotent pleomorphic sarcoma / malignant fibrous histiocytoma, fibrosarcoma , clear cell sarcoma, recurrent nasopharyngeal carcinoma, sarcoma of uterus, epithelioid sarcoma, and small-cell lung cancer, squamous non-small cell lung cancer, gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction, metastatic urothelial cancer. It is administered through intravenous route. The drug candidate is an IgG4 humanized monoclonal antibody. The therapeutic candidate targets programmed death ligand-1 (PD-L1).
It was under development for the treatment of extrahepatic cholangiocarcinoma (ECC), recurrent head and neck cancer squamous cell carcinoma, nasopharyngeal cancer, laryngeal cancer, oral cavity cancer, Hypopharyngeal Cancer, gallbladder cancer (GBC), Bile Duct Cancer (Cholangiocarcinoma), relapsed and refractory primary mediastinal b-cell lymphoma, triple negative breast cancer, small-cell lung cancer and metastatic hepatocellular carcinoma.
Apollomics overview
Apollomics is a biotechnology company that discovers and develops oncology therapies. It is investigating APL-101, a novel small molecule c-Met inhibitor (c-METi) that targets the c-Met-dysregulated pathway in gastric, hepatic, pancreatic and lung tumors; and APL-102, an oral multi-kinase inhibitor (mKi) targeting receptor tyrosine kinase (RTKs) and serine or threonine-kinases in liver, breast, colorectal, gastric cancers. The company is also evaluating APL-106 against acute myeloid leukemia (AML); APL-108 to treat multiple myeloma (MM); APL-501 and APL-102 targeting solid tumors; APL-502 and APL-801 against multiple tumors; and APL-810 for gastroenterological cancers. It operates in Taiwan and the US. Apollomics is headquartered in Foster City, California, the US.
For a complete picture of Benmelstobart’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
